uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now owns 155,168 shares in the company, valued at $1,756,501.76. The trade was a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Christian Klemt also recently made the following trade(s):

• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Price Performance

QURE stock opened at $13.15 on Friday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a 50-day moving average price of $15.05 and a 200 day moving average price of $9.81. The stock has a market cap of $640.73 million, a PE ratio of -2.65 and a beta of 0.38.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Avoro Capital Advisors LLC purchased a new position in shares of uniQure during the 4th quarter worth about $38,410,000. abrdn plc boosted its stake in shares of uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. bought a new stake in uniQure during the 3rd quarter valued at about $7,360,000. RTW Investments LP lifted its holdings in uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after buying an additional 893,625 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after buying an additional 794,459 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on QURE shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. HC Wainwright lifted their price target on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.